Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946585587> ?p ?o ?g. }
- W2946585587 endingPage "2319" @default.
- W2946585587 startingPage "2312" @default.
- W2946585587 abstract "Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma." @default.
- W2946585587 created "2019-05-29" @default.
- W2946585587 creator A5019798684 @default.
- W2946585587 creator A5020670358 @default.
- W2946585587 creator A5023964068 @default.
- W2946585587 creator A5025277206 @default.
- W2946585587 creator A5026278888 @default.
- W2946585587 creator A5026910751 @default.
- W2946585587 creator A5032047407 @default.
- W2946585587 creator A5033290575 @default.
- W2946585587 creator A5036231436 @default.
- W2946585587 creator A5040242663 @default.
- W2946585587 creator A5042013155 @default.
- W2946585587 creator A5047028269 @default.
- W2946585587 creator A5052171516 @default.
- W2946585587 creator A5055677585 @default.
- W2946585587 creator A5067211665 @default.
- W2946585587 creator A5072790450 @default.
- W2946585587 creator A5073837987 @default.
- W2946585587 creator A5075387555 @default.
- W2946585587 creator A5078033835 @default.
- W2946585587 creator A5083049912 @default.
- W2946585587 creator A5084313111 @default.
- W2946585587 creator A5084932415 @default.
- W2946585587 creator A5089855589 @default.
- W2946585587 date "2019-07-15" @default.
- W2946585587 modified "2023-10-17" @default.
- W2946585587 title "EUFOREA consensus on biologics for CRSwNP with or without asthma" @default.
- W2946585587 cites W1529898734 @default.
- W2946585587 cites W1591052090 @default.
- W2946585587 cites W1967215794 @default.
- W2946585587 cites W1999201652 @default.
- W2946585587 cites W2019535648 @default.
- W2946585587 cites W2056448247 @default.
- W2946585587 cites W2059917187 @default.
- W2946585587 cites W2098276532 @default.
- W2946585587 cites W2105880697 @default.
- W2946585587 cites W2119706375 @default.
- W2946585587 cites W2143274250 @default.
- W2946585587 cites W2159638894 @default.
- W2946585587 cites W2165726810 @default.
- W2946585587 cites W2166335802 @default.
- W2946585587 cites W2170439999 @default.
- W2946585587 cites W2185828908 @default.
- W2946585587 cites W2266684950 @default.
- W2946585587 cites W2289316671 @default.
- W2946585587 cites W2293192691 @default.
- W2946585587 cites W2324417905 @default.
- W2946585587 cites W2339358422 @default.
- W2946585587 cites W2395464839 @default.
- W2946585587 cites W2469742199 @default.
- W2946585587 cites W2515977513 @default.
- W2946585587 cites W2518686987 @default.
- W2946585587 cites W2524051065 @default.
- W2946585587 cites W2554368353 @default.
- W2946585587 cites W2556598798 @default.
- W2946585587 cites W2590824653 @default.
- W2946585587 cites W2594421110 @default.
- W2946585587 cites W2596290339 @default.
- W2946585587 cites W2610814011 @default.
- W2946585587 cites W2614953024 @default.
- W2946585587 cites W2615812620 @default.
- W2946585587 cites W2730614382 @default.
- W2946585587 cites W2731159563 @default.
- W2946585587 cites W2734059082 @default.
- W2946585587 cites W2736754684 @default.
- W2946585587 cites W2765138458 @default.
- W2946585587 cites W2765477066 @default.
- W2946585587 cites W2766150186 @default.
- W2946585587 cites W2769396190 @default.
- W2946585587 cites W2780454132 @default.
- W2946585587 cites W2783845858 @default.
- W2946585587 cites W2796394543 @default.
- W2946585587 cites W2801587651 @default.
- W2946585587 cites W2803941918 @default.
- W2946585587 cites W2804276169 @default.
- W2946585587 cites W2804382555 @default.
- W2946585587 cites W2805002966 @default.
- W2946585587 cites W2805638549 @default.
- W2946585587 cites W2810514516 @default.
- W2946585587 cites W2810856968 @default.
- W2946585587 cites W2824074660 @default.
- W2946585587 cites W2834167955 @default.
- W2946585587 cites W2885647709 @default.
- W2946585587 cites W2886174381 @default.
- W2946585587 cites W2887240272 @default.
- W2946585587 cites W2887855058 @default.
- W2946585587 cites W2891218618 @default.
- W2946585587 cites W2902723246 @default.
- W2946585587 cites W2903906519 @default.
- W2946585587 cites W2912061875 @default.
- W2946585587 cites W2913184461 @default.
- W2946585587 cites W2929943519 @default.
- W2946585587 cites W4245902212 @default.
- W2946585587 cites W4254046232 @default.
- W2946585587 cites W4294699767 @default.
- W2946585587 cites W4319429722 @default.
- W2946585587 doi "https://doi.org/10.1111/all.13875" @default.